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Calcimimetic increases osteoprotegerin and decreases
fetuin-A levels in dialysis patients
Sir,
The calcimimetic drug cinacalcet, recently introduced as
therapy for Secondary Hyper-Parathyrodism (SHP) in
dialysis patients, has greatly enhanced the ability to achieve
simultaneous control of parathyroid hormone (PTH),
calcium and phosphate [1].
However, there have been no data to show that a better
control of mineral metabolic parameters is matched with
improved clinical outcomes of vascular calcification pro-
cesses, and hence, of vascular morbidity and mortality.
Recent studies have shown that both osteoprotegerin
(OPG) and Fetuin-A are associated with the vascular
calcification process in uraemic patients [2,3].
Of 164 patients from our dialysis centre, we submitted 29
of these having serum i-PTH >300 pg/ml while on standard
therapy (calcitriolþ phosphate binders) to cinacalcet treat-
ment over a 6-month period.
After an observation period of 3 weeks that included the
standard therapy, cinacalcet was started at an initial dose of
30mg per day. Thereafter, cinacalcet, vitamin D metabolites
and phosphate binder doses were adjusted according to
i-PTH, c-Ca and Pi levels. Cinacalcet was allowed to be
increased by 30mg steps every 15 days to a maximal allowed
dose of 180mg per day. The drug was reduced or withdrawn
if i-PTH levels were <150 pg/ml, if c-Ca was <8.4mg/dl,
or if any adverse events appeared.
Blood levels of i-PTH, c-Ca, inorganic phosphate (Pi),
albumin, IL-6, Fetuin-A, OPG were assessed at baseline and
at the end of the study period. Intact PTH, c-Ca and Pi levels
were also checked every 15 days. Over the 6-month study
period, the doses of cinacalcet, vitamin D metabolites,
phosphate binders, erythropoietin (EPO), anti-hypertensive
(antiHT) drugs and any major and minor adverse events were
recorded.
OPG and Fetuin-A were assessed by ELISA (Normal
values: OPG 4.1 0.33 pmol/l; Fetuin-A 0.35–0.95 g/l).
IL-6 was determined with a solid-phase, enzyme-labelled,
chemiluminescent sequential immunometric assay (Normal
values were 0–5.9 pg/ml).
Five of the original 29 patients did not complete the study
(two due to cardio-vascular deaths; one for withdrawal after
a non-fatal cardio-vascular event; two for receiving renal
transplantation), resulting in 24 patients included in the final
analysis (16 males; aged 38–78).
Table 1 shows the effects of cinacalcet treatment on
i-PTH, c-Ca, Pi and the c-CaPi product. All of these
parameters were significantly decreased after cinacalcet
therapy.
The mean dose of cinacalcet utilized at the end of the study
was 63.12 40.3mg per day. There were no significant
changes in Vitamin D, Sevelamer, Ca based Pi binder,
antiHT drugs or EPO doses.
Following cinacalcet treatment, mean serum OPG levels
were significantly increased and serum Fetuin-A levels
were significantly decreased (Table 2). On the other hand,
there were no significant changes in mean IL-6 values. OPG
increments were significantly correlated with the degree of
c-Ca reduction (r¼ 0.445; P¼ 0.029), whereas Fetuin-A
Table 1. Effects of 6-month Cinacalcet treatment on the main
mineral metabolic parameters and doses of concomitant therapy
(mean SD)
Baseline 6th month P
i-PTH pg/ml 714.0 410.1 379.8 439.1 0.0002
c-Ca mg/dl 10.52 0.94 9.10 0.72 0.00001
Pi mg/dl 4.93 1.33 4.20 1.97 0.0032
CaPi mg2/dl2 51.9 14.9 38.1 10.5 <0.00001
Vitamin D
therapy (mg/week)
2.05 1.84 1.63 1.36 0.331
Ca carbonate 0.442 0.754 0.480 0.556 0.726
(g/day of
elemental Ca)
Sevelamer (g/day) 5.43 2.90 5.00 2.80 0.319
Table 2. Effects of cinacalcet on OPG, Fetuin-A and IL-6 levels
(mean SD)
Baseline 6th month P
OPG (pmol/l) 16.61 13.4 22.20 16.7 0.001
Fetuin-A (g/l) 0.766 0.44 0.430 0.24 0.01
IL-6 (pg/ml) 5.75 4.37 5.93 5.19 0.847
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reductions were correlated with reductions in i-PTH levels
(r¼ 0.495; P¼ 0.024). There were no relationships between
IL-6 changes and the main mineral metabolism related
parameters.
Our results agree with previous experimental findings [4]
and point to the efficacy of calcimimetic drugs for the control
of uraemic SHP.
It was unexpected that 6 months of cinacalcet treatment
resulted in highly significant increases in OPG and decreases
in Fetuin-A serum levels.
OPG, a cytokine produced and secreted mainly by
osteoblasts, has been claimed to play an as yet undefined
role in the vascular calcification process. Although a
protective effect of increased OPG levels on vascular
calcification has been suggested, higher OPG serum levels
have been linked to an increased extent of arterial wall
calcification, increased mortality rates in uraemic patients,
and most importantly, with increased mortality in dialysis
patients [3,5]. The clinical significance of the OPG increase
observed in our patients and its potential effects on the
vascular calcification process cannot be drawn from
our data. Interestingly, OPG increases were significantly
correlated with the degree of reduction in c-Ca levels.
In association with the OPG increases, cinacalcet treatment
also caused significant decreases in Fetuin-A levels without
changes in IL-6, indicating no change in the inflammatory
state in our patients. The Fetuin-A reduction was signifi-
cantly related to PTH decreases. Previous studies have
emphasized an association between low Fetuin-A levels
with both increased vascular calcification and cardiovascular
mortality [2,6]. From our data, we cannot determine whether
the Fetuin-A decrease represents a real increase in risk for the
calcification process, or whether it is the consequence of a
reduced demand for a feedback defence mechanism, which
may be secondary to improved mineral metabolism, by
cinacalcet, that reduces the pro-calcification burden. This
possibility was proposed in non-dialysed diabetic nephro-
pathy patients [7].
Although we are aware of the main limitation of
this preliminary study, the highly significant changes in
both OPG and Fetuin-A levels observed in our patients
provide a stimulus and starting point for further research
in this field.
Acknowledgements. This study was supported by the grant: ‘Project
Glomerulonephritis’ in memory of Pippo Neglia.
Conflict of interest statement. Dr Piergiorgio Messa received lecture
fees from AMGEN, ABBOTT, and DOMPE’ BIOTEC. The other
authors have no conflict of interest to declare.
1Nephrology, Dialysis and
Transplant Unit, Department of
Medicine and
2Clinical Pathology Laboratory
Ospedale Maggiore-Policlinico-
MaRe-IRCCS,
Fondazione, Milano, Italy
Email: pmessa@policlinico.mi.it
Piergiorgio Messa1
Loredana Alberti1
Giovanna Como1
Roberta Cerutti1
Bianca Mandujano1
Silvia Tirelli2
Erminio Torresani2
Brigida Brezzi1
1. Moe SM, Chertow GM, Coburn JW. Achieving NKF-K/
DOQITM bone metabolism and treatment goals with cinacalcet
HCl. Kidney Int 2005; 67: 760–771
2. Ketteler M. Fetuin-A and extraosseous calcification in uremia.
Curr Opin Nephrol Hypertens 2005; 14: 337–342
3. Kiechl S, Schett G, Wenning G et al. Osteoprotegerin is a risk
factor for progressive atherosclerosis and cardiovascular disease.
Circulation 2004; 109: 2175–2180
4. Pritzker LB, Scatena M, Giachelli CM. The role of osteopro-
tegerin and tumor necrosis factor-related apoptosis-inducing
ligand in human microvascular endothelial cell survival.
Mol Biol Cell 2004; 15: 2834–2841
5. Morena M, Terrier N, Jaussent I et al. Plasma osteoprotegerin is
associated with mortality in hemodialysis patients. J Am Soc
Nephrol 2006; 17: 262–270
6. Stenvinkel P, Wang K, Qureshi AR et al. Low Fetuin-A levels
are associated with cardiovascular death: impact of variations
in the gene encoding fetuin. Kidney Int 2005; 67: 2383–2392
7. Mehrotra R, Westenfeld R, Christenson P et al. Serum Fetuin-A
in non-dialysed patients with diabetic nephropathy: relationship
with coronary artery calcification. Kidney Int 2005; 67:
1070–1077
doi:10.1093/ndt/gfm312
Advance Access publication 25 May 2007
Does size matter?
Sir,
In the November 2006 issue of JASN, Opelz et al. published
their analysis of the association of ACEI/ARB with patient
and graft survival after renal transplantation utilizing the
CTS registry [1]. In contrast to our study, published in JASN
in March 2006, Opelz and colleagues reported that they
failed to find such an association [2].
How can that be?
(i) There are differences in the group definitions and
inclusion criteria between the two studies. While we
included all patients transplanted between 1990
and 2003 with a functioning graft 3 months after
transplantation, Opelz et al. used only patients trans-
planted between 1995 and 2004, with functioning graft
1 year after transplantation.
(ii) There are differences in the way ACEI/ARB enters the
analysis. While we used ACEI/ARB intake as a time-
dependent variable, and only for graphical illustration
divided our patients into those who had received ACEI/
ARB treatment after transplantation and those who had
never received such treatment, Opelz et al. used ACEI/
ARB in a fixed manner, comparing groups based on
ACEI/ARB treatment at the time of 1 year after
transplantation. In order to compare these results to
ours, we performed a re-analysis of our database,
including only patients transplanted from 1995 on and
only those who had a functioning graft 1 year after
transplantation. Then we used the same group
definition as Opelz and colleagues and compared
our new results to their and our published ones.
We obtained the following survival curves (restricted
to 6 years of follow-up, as in the publication of
Opelz et al.) (Figure 1).
At 6 years of follow-up, the survival rates are comparable
(Table 1).
We computed the crude (unadjusted for confounding)
hazard ratio (HR) for ACEI/ARB use with the reduced data
base, for graft and patient survival. These hazard ratio
estimates compare to the results based on time-varying entry
of ACEI/ARB use are displayed in Table 2.
Nephrol Dial Transplant (2007) 22: 2725 2725
D
ow
nloaded from
 https://academ
ic.oup.com
/ndt/article-abstract/22/9/2724/1842473 by guest on 13 N
ovem
ber 2018
